Bb Biotech Ag Has Trimmed Stake in Celgene Corp (CELG) as Shares Declined

January 19, 2018 - By Adrian Erickson

Investors sentiment decreased to 1.17 in 2017 Q3. Its down 0.17, from 1.34 in 2017Q2. It is negative, as 44 investors sold CELG shares while 457 reduced holdings. 133 funds opened positions while 451 raised stakes. 603.99 million shares or 0.25% more from 602.51 million shares in 2017Q2 were reported. Wolverine Asset Management Ltd Liability Corporation reported 113,141 shares stake. Bbva Compass Bancorp holds 21,900 shares or 0.21% of its portfolio. Todd Asset Ltd Liability Com reported 0.99% in Celgene Corporation (NASDAQ:CELG). Bartlett And Ltd has invested 0.01% in Celgene Corporation (NASDAQ:CELG). Prns Ltd Limited Liability Company holds 66,921 shares or 0.32% of its portfolio. Bluemountain Cap Mngmt Limited Com has invested 0.15% in Celgene Corporation (NASDAQ:CELG). 682,480 are held by Banque Pictet Cie Sa. Illinois-based Great Lakes Advsr has invested 0.01% in Celgene Corporation (NASDAQ:CELG). Bradley Foster And Sargent Ct, Connecticut-based fund reported 63,622 shares. Geode Cap Mngmt Llc invested in 7.96M shares or 0.43% of the stock. Dana Investment Advsr holds 0.37% or 55,279 shares in its portfolio. State Of New Jersey Common Pension Fund D invested 0.3% of its portfolio in Celgene Corporation (NASDAQ:CELG). Chilton Capital Mngmt Ltd Liability Com holds 1.08% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 77,227 shares. C Group A S reported 179,019 shares. Dorsey And Whitney Trust Lc has invested 0.06% in Celgene Corporation (NASDAQ:CELG).

Since August 2, 2017, it had 0 insider buys, and 5 insider sales for $6.27 million activity. $248,498 worth of Celgene Corporation (NASDAQ:CELG) was sold by Curran Terrie on Monday, September 25. KAPLAN GILLA sold $1.01 million worth of Celgene Corporation (NASDAQ:CELG) on Wednesday, August 2. CASEY MICHAEL D sold $1.29M worth of stock.

Bb Biotech Ag decreased its stake in Celgene Corp (CELG) by 2% based on its latest 2017Q3 regulatory filing with the SEC. Bb Biotech Ag sold 65,000 shares as the company’s stock declined 3.49% while stock markets rallied. The institutional investor held 3.18M shares of the major pharmaceuticals company at the end of 2017Q3, valued at $464.33 million, down from 3.25M at the end of the previous reported quarter. Bb Biotech Ag who had been investing in Celgene Corp for a number of months, seems to be less bullish one the $80.09B market cap company. The stock decreased 0.29% or $0.3 during the last trading session, reaching $101.72. About 9.28M shares traded or 8.30% up from the average. Celgene Corporation (NASDAQ:CELG) has risen 17.00% since January 19, 2017 and is uptrending. It has outperformed by 0.30% the S&P500.

Bb Biotech Ag, which manages about $3.61B US Long portfolio, upped its stake in Esperion Therapeutics Inc. (NASDAQ:ESPR) by 584,422 shares to 2.10M shares, valued at $105.15 million in 2017Q3, according to the filing. It also increased its holding in Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) by 25,000 shares in the quarter, for a total of 205,000 shares, and has risen its stake in Tesaro Inc. (NASDAQ:TSRO).

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on January, 25. They expect $1.75 earnings per share, up 24.11 % or $0.34 from last year’s $1.41 per share. CELG’s profit will be $1.38B for 14.53 P/E if the $1.75 EPS becomes a reality. After $1.78 actual earnings per share reported by Celgene Corporation for the previous quarter, Wall Street now forecasts -1.69 % negative EPS growth.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Investorplace.com which released: “Celgene Corporation Stock Needs More Than a Juno Acquisition to Thrive” on January 19, 2018, also Seekingalpha.com with their article: “Celgene Tries To Rejoin The Party” published on January 10, 2018, Seekingalpha.com published: “Celgene – Strong Portfolio Should Support Growing Earnings” on January 09, 2018. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Seekingalpha.com and their article: “Celgene: Impact Biomedicines To Broaden The Pipeline” published on January 09, 2018 as well as Seekingalpha.com‘s news article titled: “Celgene: Parsing Through The $7 Billion Impact Acquisition” with publication date: January 10, 2018.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 33 analysts covering Celgene Corporation (NASDAQ:CELG), 18 have Buy rating, 2 Sell and 13 Hold. Therefore 55% are positive. Celgene Corporation had 124 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by Stifel Nicolaus on Monday, January 8 with “Buy”. Wells Fargo maintained the shares of CELG in report on Friday, December 4 with “Outperform” rating. Leerink Swann initiated the stock with “Market Perform” rating in Friday, February 5 report. The firm has “Buy” rating given on Friday, October 27 by UBS. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Sunday, August 13 by Jefferies. The firm has “Buy” rating by SunTrust given on Thursday, January 7. The rating was maintained by JMP Securities on Friday, July 24 with “Mkt Outperform”. The firm earned “Hold” rating on Friday, October 20 by Citigroup. On Friday, January 29 the stock rating was maintained by RBC Capital Markets with “Outperform”. As per Friday, November 6, the company rating was maintained by UBS.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.